Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Files An 8-K Other EventsItem 8.01 Other Events.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Files An 8-K Other Events
On June 1, 2017, Momenta Pharmaceuticals, Inc. (the “Company”) announced that Santiago Arroyo, M.D., Ph.D., former Chief Medical Officer of Boston Pharmaceuticals, has been appointed to the position of Chief Medical Officer and Senior Vice President, Development.
About Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Recent Trading Information
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) closed its last trading session down -0.15 at 14.50 with 1,992,423 shares trading hands.
Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. It focuses on three product areas: Complex Generics, Biosimilars and Novel Therapeutics. It has developed generic version of Lovenox (enoxaparin sodium injection). Its GLATOPA is a generic version of once-daily COPAXONE 20 milligrams/milliliter (mg/mL) indicated for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS), a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. It is developing M923, which is a biosimilar of HUMIRA and M834 as a biosimilar of ORENCIA. Its oncology product candidate Necuparanib, is an oncology product candidate, which have a range of effects on tumor cells and the environment, in which tumor cells grow. It focuses on M281, which is an Anti-FcRn program. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Recent Trading Information
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) closed its last trading session down -0.15 at 14.50 with 1,992,423 shares trading hands.
